NASDAQ:TRAW Traws Pharma Q3 2025 Earnings Report $0.58 +0.02 (+2.81%) Closing price 04:00 PM EasternExtended Trading$0.56 -0.02 (-3.11%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Traws Pharma EPS ResultsActual EPS-$0.34Consensus EPS -$9.16Beat/MissBeat by +$8.82One Year Ago EPSN/ATraws Pharma Revenue ResultsActual RevenueN/AExpected Revenue$0.06 millionBeat/MissN/AYoY Revenue GrowthN/ATraws Pharma Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time7:00AM ETUpcoming EarningsTraws Pharma's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Traws Pharma Earnings HeadlinesTraws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Recommendation of "Reduce" by BrokeragesSeptember 23, 2026 | americanbankingnews.comTraws Pharma (NASDAQ:TRAW) Trading 0% Higher - Should You Buy?September 23, 2026 | americanbankingnews.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.September 28 at 1:00 AM | Stansberry Research (Ad)Traws Pharma shares rise after Q2 loss comes in better than expectedAugust 17, 2026 | finance.yahoo.comTraws Pharma Reports Q2 2026 Financial Results and Provides Business HighlightsAugust 14, 2026 | globenewswire.comTraws Pharma Announces New At-The-Market Offering ProgramJuly 10, 2026 | tipranks.comSee More Traws Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email. Email Address About Traws PharmaTraws Pharma (NASDAQ:TRAW) (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral infections and cancer. The company’s programs are focused on addressing diseases with significant unmet medical needs, and its candidates remain in clinical development rather than being marketed as approved products. Traws Pharma’s antiviral portfolio includes tivoxavir marboxil, an investigational oral treatment designed to inhibit the influenza virus cap-dependent endonuclease and potentially treat influenza A and B infections. The company is also developing oncology candidate narazaciclib, a next-generation cyclin-dependent kinase 4/6 inhibitor being studied for potential use in cancer treatment. The company was formerly known as Onconova Therapeutics, Inc. and adopted the Traws Pharma name as it expanded its focus to include respiratory antiviral development. Traws Pharma is headquartered in Newtown, Pennsylvania, and conducts research and clinical development activities intended to support potential treatment applications in international markets.View Traws Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
